Abstract 62P
Background
According to the GLOBOCAN database 2020, colorectal cancer (CRC) has the fourth-highest incidence in Indonesia. In Yogyakarta province, CRC is the third most prevalent cancer. CRC usually present with common gastrointestinal complaints. The relationship between the chief complaint and clinicopathology parameters has been rarely explored in Indonesia. We, therefore, aimed to analyze their association with our CRC patients.
Methods
A retrospective study was done on 1,276 CRC cases diagnosed between January 2016 and December 2019 at Dr. Sardjito Hospital, Yogyakarta. We collected secondary data from the CRC clinical registry database, including demography, chief complaints and clinicopathology features. Data on hospitals where CRC diagnostic procedure was performed based on biopsy or resection. Chi-square analysis was used to determine the relationship between the chief complaint and clinicopathology parameters.
Results
The most common chief complaints were hematochezia (34.4.%), bloating (24.8%), constipation (23%), diarrhea (17.5%), weight loss (12.1%) and abdominal mass (9.8%). Hematochezia was associated with tumor site, T status, N status, M status, clinical stage, performance status, and type of diagnostic hospital. Diarrhea was associated with age, hemoglobin, serum albumin, and type of diagnostic hospital. Constipation was associated with gender, tumor site, N status, serum albumin, and type of diagnostic hospital. Bloating was associated with tumor site, M status, clinical stage, histological grade, serum albumin, performance status, and type of diagnostic hospital. Weight loss was related to the tumor site, M status and diagnostic hospital. Abdominal mass was associated with age, gender, and serum albumin. All p values were < 0.05.
Conclusions
The chief complaints of CRC were associated with various clinicopathological parameters that may influence the patient's prognosis. Because complaints associated with CRC are similar to other gastrointestinal diseases, the awareness of clinicians to immediately follow up is needed so that patients can be identified at an earlier stage. Referral process across hospitals may also serve as a target for health system improvement.
Clinical trial identification
Editorial acknowledgement
The authors thank Yana Suryani, Rosita Yunanda Purwanto, and Nugira Dinantia for technical assistance and coordination.
Legal entity responsible for the study
Yasjudan Rastrama Putra.
Funding
The authors received financial support from the Applied Research Grant 2020–2021, The Indonesian Ministry of Research, Technology, and Higher Education and the Institutional Links grant, ID 527558574, under the Newton Institutional Link-Indonesia KLN Fund partnership, funded by the UK Department for Business, Energy and Industrial Strategy and Indonesia Ministry of Research Technology & Higher Education and delivered by the British Council.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
79P - Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study
Presenter: Arndt Vogel
Session: Poster viewing 02
82P - A randomized controlled, open-label, adaptive phase III clinical trial to evaluate safety and efficacy of EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas after FOLFIRINOX
Presenter: Muh-Hwan Su
Session: Poster viewing 02
83P - Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster viewing 02
84P - Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population
Presenter: Margherita Rimini
Session: Poster viewing 02
86P - Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Aiwu Ruth He
Session: Poster viewing 02
87P - Socio-demographic disparities in esophageal cancer: A SEER analysis
Presenter: Beas Siromoni
Session: Poster viewing 02
88P - Sintilimab plus anlotinib as second-line therapy for metastatic or recurrent gallbladder carcinoma (GBC): A single-arm, phase II study
Presenter: Qingbao Cheng
Session: Poster viewing 02